295 related articles for article (PubMed ID: 37182736)
1. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
Yao JM; Otoukesh S; Kim H; Yang D; Mokhtari S; Samara Y; Blackmon A; Arslan S; Agrawal V; Pourhassan H; Amanam I; Ball B; Koller P; Salhotra A; Becker P; Curtin P; Artz A; Aldoss I; Ali H; Stewart F; Smith E; Stein A; Marcucci G; Forman SJ; Nakamura R; Al Malki MM
Transplant Cell Ther; 2023 Aug; 29(8):515.e1-515.e7. PubMed ID: 37182736
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Papanicolaou GA; Chen M; He N; Martens MJ; Kim S; Batista MV; Bhatt NS; Hematti P; Hill JA; Liu H; Nathan S; Seftel MD; Sharma A; Waller EK; Wingard JR; Young JH; Dandoy CE; Perales MA; Chemaly RF; Riches M; Ustun C
Transplant Cell Ther; 2024 Jan; 30(1):114.e1-114.e16. PubMed ID: 37775070
[TBL] [Abstract][Full Text] [Related]
3. Reduced Cytokine Release Syndrome and Improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical Stem Cell Transplantation.
Tang J; Jensen RR; Bryan B; Hoda D; Hunter BD
Transplant Cell Ther; 2024 Apr; 30(4):438.e1-438.e11. PubMed ID: 38281591
[TBL] [Abstract][Full Text] [Related]
4. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
Elmariah H; Otoukesh S; Kumar A; Ali H; Arslan S; Shouse G; Pourhassan H; Nishihori T; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Locke F; Bejanyan N; Al Malki MM
Transplant Cell Ther; 2024 Feb; 30(2):229.e1-229.e11. PubMed ID: 37952648
[TBL] [Abstract][Full Text] [Related]
6. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
Otoukesh S; Elmariah H; Yang D; Clark MC; Siraj M; Ali H; Mogili K; Arslan S; Nishihori T; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Al Malki MM; Bejanyan N
Transplant Cell Ther; 2022 Feb; 28(2):111.e1-111.e8. PubMed ID: 34844022
[TBL] [Abstract][Full Text] [Related]
7. Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation.
Salas MQ; Atenafu EG; Law AD; Lam W; Pasic I; Chen C; Dong Hwan Kim D; Michelis FV; Gerbitz A; Lipton JH; Mattsson J; Kumar R; Viswabandya A
Transplant Cell Ther; 2021 May; 27(5):428.e1-428.e9. PubMed ID: 33965185
[TBL] [Abstract][Full Text] [Related]
8. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
Ahmed S; Kanakry JA; Ahn KW; Litovich C; Abdel-Azim H; Aljurf M; Bacher VU; Bejanyan N; Cohen JB; Farooq U; Fuchs EJ; Bolaños-Meade J; Ghosh N; Herrera AF; Hossain NM; Inwards D; Kanate AS; Martino R; Munshi PN; Murthy H; Mussetti A; Nieto Y; Perales MA; Romee R; Savani BN; Seo S; Wirk B; Yared JA; Sureda A; Fenske TS; Hamadani M
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1859-1868. PubMed ID: 31132455
[TBL] [Abstract][Full Text] [Related]
9. Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide.
Kurita N; Sakamoto T; Kato T; Kusakabe M; Yokoyama Y; Nishikii H; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
Ann Hematol; 2021 May; 100(5):1295-1301. PubMed ID: 33580280
[TBL] [Abstract][Full Text] [Related]
10. Cytokine release syndrome after haploidentical hematopoietic stem cell transplantation with antithymocyte globulin: risk factors analysis and poor impact on outcomes for non-remisssion patients.
Xu Z; Zhou X; Zhao X; Lu X; Tang L; Shi W; Yan H; You Y; Wang H
Hematology; 2021 Dec; 26(1):809-817. PubMed ID: 34602023
[TBL] [Abstract][Full Text] [Related]
11. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients.
Wang Y; Wu DP; Liu QF; Xu LP; Liu KY; Zhang XH; Yu WJ; Xu Y; Huang F; Huang XJ
J Hematol Oncol; 2019 Sep; 12(1):88. PubMed ID: 31481121
[TBL] [Abstract][Full Text] [Related]
12. Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide.
Solán L; Landete E; Bailén R; Dorado N; Oarbeascoa G; Anguita J; Díez-Martín JL; Kwon M
Hematol Oncol; 2020 Oct; 38(4):597-603. PubMed ID: 32592410
[TBL] [Abstract][Full Text] [Related]
13. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide.
Rappazzo KC; Zahurak M; Bettinotti M; Ali SA; Ambinder AJ; Bolaños-Meade J; Borrello I; Dezern AE; Gladstone D; Gocke C; Fuchs E; Huff CA; Imus PH; Jain T; Luznik L; Rahmat L; Swinnen LJ; Wagner-Johnston N; Jones RJ; Ambinder RF
Transplant Cell Ther; 2021 Nov; 27(11):909.e1-909.e6. PubMed ID: 34425261
[TBL] [Abstract][Full Text] [Related]
14. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
15. Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation.
Wada F; Kanda J; Kamijo K; Nishikubo M; Yoshioka S; Ishikawa T; Ueda Y; Akasaka T; Arai Y; Izumi K; Hirata H; Ikeda T; Yonezawa A; Anzai N; Watanabe M; Imada K; Yago K; Tamura N; Itoh M; Masuo Y; Kunitomi A; Takeoka T; Kitano T; Arima N; Hishizawa M; Asagoe K; Kondo T; Takaori-Kondo A
Cell Transplant; 2023; 32():9636897231194497. PubMed ID: 37646153
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus Umbilical Cord Blood Transplantation in Adult Patients with Aplastic Anemia.
Onishi Y; Mori T; Yamazaki H; Hiramoto N; Zaimoku Y; Kanaya M; Matsue K; Onizuka M; Aotsuka N; Uchida N; Onodera K; Kanda J; Nakamae H; Yamamoto R; Kuriyama T; Kimura T; Ichinohe T; Atsuta Y;
Transplant Cell Ther; 2023 Dec; 29(12):766.e1-766.e8. PubMed ID: 37730121
[TBL] [Abstract][Full Text] [Related]
17. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
[TBL] [Abstract][Full Text] [Related]
19. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
20. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome.
Raj RV; Hamadani M; Szabo A; Pasquini MC; Shah NN; Drobyski WR; Shaw BE; Saber W; Rizzo JD; Jerkins J; Fenske TS; D'Souza A; Dhakal B; Zhang C; Konings S; Hari PN; Chhabra S
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1664-1670. PubMed ID: 29680516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]